SuperworthCastle Biosciences EPS CSTL
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$0.66
- Latest quarter, Q2 FY26
- −$0.07
- −147% on a year earlier
- Fiscal year 2025
- −$0.85
- −239% on the year before
Castle Biosciences' earnings per share was −$0.66 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.07, down 147% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.85 | −239% |
| FY2024 | $0.61 | n/a |
| FY2023 | −$2.16 | n/a |
| FY2022 | −$2.58 | n/a |
| FY2021 | −$1.24 | n/a |
| FY2020 | −$0.51 | n/a |
| FY2019 | −$2.11 | n/a |
| FY2018 | −$5.36 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.07 | −147% | −$0.66 | |
| Q1 FY26 | −$0.49 | n/a | −$0.44 | |
| Q4 FY25 | −$0.08 | −126% | −$0.85 | |
| Q3 FY25 | −$0.02 | −125% | −$0.46 | |
| Q2 FY25 | $0.15 | −52% | −$0.36 | |
| Q1 FY25 | −$0.90 | n/a | −$0.20 | |
| Q4 FY24 | $0.31 | n/a | $0.61 | |
| Q3 FY24 | $0.08 | n/a | $0.20 | |
| Q2 FY24 | $0.31 | n/a | −$0.14 | |
| Q1 FY24 | −$0.09 | n/a | −$1.15 | |
| Q4 FY23 | −$0.10 | n/a | −$2.16 | |
| Q3 FY23 | −$0.26 | n/a | −$2.84 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Castle Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CSTLCastle Biosciences | −$0.66 | |
| NRCNRC Health | $0.25 | −67% a year |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| BLLNBillionToOne | $0.65 | |
| LNTHLantheus | $4.13 | +10% a year |
| CAICaris Life Sciences | $0.37 | |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| Peer median | $1.40 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Castle Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.